MoonLake Immunotherapeutics(MLTX)

Focus: MoonLake is a newly public (2024) Swiss biotech focused on tri-specific nanobody therapeutics, currently in clinical development across dermatology and rheumatology indications with a lean 51-200 person team.

Dermatology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

About MoonLake Immunotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow MoonLake Immunotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Sonelokimab

Relative Bioequivalence

PHASE_1

Clinical Trials (1)

NCT06994936An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Phase 1

Help build intelligence for MoonLake Immunotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Concentrated focus on one well-advanced clinical program (Sonelokimab) with 7 Phase 3 trials across two high-value indications—provides clear visibility into near-term value creation
Recently public company with substantial cash position ($180M as of FY2025) and proven access to capital markets—reduces near-term restructuring risk
Proprietary tri-specific nanobody platform is differentiated from monoclonal antibodies; small team means broad exposure to clinical, regulatory, and commercial strategy

Watch Out For

Zero active job openings reported and only 51-200 headcount suggests limited hiring velocity and narrow career ladder advancement opportunities
Company is pre-revenue and burning cash ($36M net loss in FY2025, $49M in FY2024); commercialization success is entirely dependent on Phase 3 outcomes

Generated by Claude from MoonLake Immunotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sonelokimab

Hidradenitis Suppurativa

PHASE_2

Clinical Trials (1)

NCT05322473Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Phase 2

Sonelokimab

Arthritis, Psoriatic

PHASE_2

Clinical Trials (1)

NCT05640245Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Phase 2

Sonelokimab

Arthritis, Psoriatic

PHASE_3

Clinical Trials (1)

NCT07223138A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Phase 3

Sonelokimab

Hidradenitis Suppurativa

PHASE_3

Clinical Trials (1)

NCT06411379Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Sonelokimab

Hidradenitis Suppurativa

PHASE_3

Clinical Trials (1)

NCT07007637A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Sonelokimab

Hidradenitis Suppurativa

PHASE_3

Clinical Trials (1)

NCT06411899A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Sonelokimab

Hidradenitis Suppurativa

PHASE_3

Clinical Trials (1)

NCT06768671An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Phase 3

Sonelokimab

Arthritis, Psoriatic

PHASE_3

Clinical Trials (1)

NCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Phase 3

Sonelokimab

Arthritis, Psoriatic

PHASE_3

Clinical Trials (1)

NCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug